I migliori Acute Myeloid Leukemia podcast (2024)

1
Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma 57:58

1d ago57:58

57:58

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.…

1
Practical Perspectives: Current Management of Chronic Myeloid Leukemia 1:49:21

7d ago1:49:21

1:49:21

Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.Di Neil Love, MD

1
Blood Transfusion Safety: TRALI vs TACO 20:03

9d ago20:03

20:03

Join us as we explore blood transfusion safety, focusing specifically on Transfusion-Related Acute Lung Injury (TRALI) and Transfusion-Associated Circulatory Overload (TACO). Tailored for general hematologists with a foundational understanding of transfusion medicine, this session delves into the pathophysiology, clinical presentation, diagnostic c…

1
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies 20:40

9d ago20:40

20:40

In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including: 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D The role of bispecific antibodies in R/R MM Safety considerations for patients while receiving a bispecific antibody Emerging…

1
Oncology Today with Dr Neil Love: Peripheral T-Cell Lymphoma 46:32

15d ago46:32

46:32

Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas.Di Neil Love, MD

1
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations 28:28

16d ago28:28

28:28

In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including: The diagnosis and typical presenting symptoms of GEP-NETs Findings from recent key phase III studies including NETTER-2 and CABINET Recommendations for treatment sequencing No…

1
Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series 58:58

22d ago58:58

58:58

Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.Di Neil Love, MD

1
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers 30:45

1M ago30:45

30:45

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including: Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced…

1
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance 32:48

1M ago32:48

32:48

In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including: Contemporary treatment paradigms for patients with CLL Safety and efficacy of current regimens Molecular testing, including when and how to test for BTK inhibitor res…

1
Advancing Sickle Cell Disease Care: Navigating Gene Therapy 17:11

2M ago17:11

17:11

Are you a hematologist or a generalist provider seeking clarity on how to best counsel patients with sickle cell disease (SCD) who are interested in gene therapy? Join us for a podcast session focused on important patient considerations for gene therapy, tailored for SCD providers and clinicians. This session aims to provide practical insights to f…

1
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC 13:53

2M ago13:53

13:53

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including: Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advan…

1
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC 13:46

2M ago13:46

13:46

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including: Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC Long-term safety observations for cri…

1
ROS1-Alterations and Molecular Testing in Advanced NSCLC 16:28

2M ago16:28

16:28

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including: ROS1-gene fusions in advanced lung cancer ROS1 testing recommendations with DNA …

1
Updates in Thalassemia: New Challenges and Novel Treatment Approaches 20:19

2M ago20:19

20:19

Speakers: Alexis Thompson, MD, and Sujit Sheth, MD Description: For general hematologists with a foundational understanding of thalassemia, this episode discusses the changing demographics due to immigration and refugee resettlement. It covers the diagnosis process from newborn screening to older individuals, emphasizing genetic testing due to nume…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma 1:02:03

3M ago1:02:03

1:02:03

Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma.Di Neil Love, MD

1
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers 49:32

3M ago49:32

49:32

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including: RUBY Part 1 Subgroup …

1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs 34:45

3M ago34:45

34:45

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…

1
Current Clinical Practice and NCCN Guidelines for CLL/SLL 31:33

4M ago31:33

31:33

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…

1
RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma 1:00:49

4M ago1:00:49

1:00:49

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs 28:35

4M ago28:35

28:35

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…

1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways 24:23

4M ago24:23

24:23

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…

1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer 24:30

4M ago24:30

24:30

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…

1
Congress to Clinic: Expert Takeaways on Emerging Data for AML 25:21

4M ago25:21

25:21

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS 19:19

4M ago19:19

19:19

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis 1:00:06

4M ago1:00:06

1:00:06

Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.Di Neil Love, MD

1
Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences 1:16:45

5M ago1:16:45

1:16:45

Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.Di Neil Love, MD

1
Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 33:54

5M ago33:54

33:54

Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Di Neil Love, MD

1
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma 42:08

5M ago42:08

42:08

Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.Di Neil Love, MD

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia 1:02:06

6M ago1:02:06

1:02:06

Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.Di Neil Love, MD

1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer 25:55

6M ago25:55

25:55

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…

1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 47:23

6M ago47:23

47:23

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…

1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series 1:01:09

6M ago1:01:09

1:01:09

Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.Di Neil Love, MD

1
Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria 1:37:16

6M ago1:37:16

1:37:16

Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.Di Neil Love, MD

1
Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences 1:04:36

6M ago1:04:36

1:04:36

Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.Di Neil Love, MD

1
Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences 1:35:11

7M ago1:35:11

1:35:11

Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.Di Neil Love, MD

1
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer 48:15

7M ago48:15

48:15

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma 1:00:13

7M ago1:00:13

1:00:13

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.Di Neil Love, MD

1
Episode #6: Grief Comparison Shopping 17:47

7M ago17:47

17:47

As grievers, it's natural to compare our journeys to others. Then, we can get into some tit for tat about whose story is "better" or "worse." Here, I share a little about why I think it's natural to do this and when I think it can hurt or help us. (Music credit: Scott Holmes)Di Brian

1
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer 36:29

8M ago36:29

36:29

In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatmen…

1
Acute Myeloid Leukemia, Part II

8M ago

—

Leukemia is a medical term for cancer of the blood cells. Acute Myeloid Leukemia, known as AML is the most common acute leukemia in adults. AML is rapidly lethal if untreated, but overall survival has improved for those under age 65 from just 8 months in the late 1970s to 46 months in 2014. We’ll have […]…

1
Acute Myeloid Leukemia, Part I

8M ago

—

Leukemia is a medical term for cancer of the blood cells. Acute Myeloid Leukemia, known as AML is the most common acute leukemia in adults. AML is rapidly lethal if untreated, but overall survival has improved for those under age 65 from just 8 months in the late 1970s to 46 months in 2014. We’ll have […]…

1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series 1:00:12

8M ago1:00:12

1:00:12

Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.Di Research To Practice

1
Episode 5: Creativity and Grief 26:13

8M ago26:13

26:13

It's a not so humble opinion of mine that indulging in creative efforts can change any human being's life. One of my greatest joys in raising my daughter was seeing her curiosity and passion for art. There were times when I embraced that side of her and other times when I could have been better. I made the mistake of passing off creativity as somet…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia 58:01

8M ago58:01

58:01

Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.Di Neil Love, MD

1
Episode 4: 7 Year Look Back: 3 Things I'd Say to Myself in My First Year of Grief 23:12

8M ago23:12

23:12

In this episode I share the three things I would tell myself if I were able to go back in time and give advice to myself in that first year after losing my daughter. (Music credit: Scott Holmes)Di Brian

1
Multiple Myeloma in Underrepresented Populations: Treatment Considerations 24:04

9M ago24:04

24:04

Dr. Azam Farooqui (@azamfarooqui ) and Dr. Monique Hartley-Brown (@DrMHB1) discuss therapeutic considerations regarding current and emerging agents for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! P…

1
Multiple Myeloma in Underrepresented Populations: Survival Outcomes 18:54

9M ago18:54

18:54

Dr. Azam Farooqui (@azamfarooqui )and Dr. Sikander Ailawadhi answer the question: Why do we need earlier diagnosis and intervention in patients with multiple myeloma from underrepresented racial and ethnic groups? Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will …

1
Multiple Myeloma in Underrepresented Populations: Clinical Risk 16:42

9M ago16:42

16:42

Dr. Azam Farooqui (@azamfarooqui) and Dr. Urvi Shah (@UrviShahMD) identify factors that impact outcomes for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased abilit…

Podcast che vale la pena ascoltare

Podcast di Acute Myeloid Leukemia

Podcast che vale la pena ascoltare

Guida rapida